Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts

被引：139
|
作者：
Zheng, Ping-Pin [1 ,2 ]
Kros, Johan M. [2 ]
Li, Jin [3 ]
机构：
[1] Erasmus MC, Drug Tox Res, Rotterdam, Netherlands
[2] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
[3] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Oncol, Shanghai, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2018年 / 23卷 / 06期
关键词：
CHIMERIC ANTIGEN RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR LYSIS SYNDROME; B-CELL; ADOPTIVE IMMUNOTHERAPY; MOLECULAR-PATTERNS; EFFICACY; SUBSETS; CANCER;
D O I：
10.1016/j.drudis.2018.02.012
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah (TM) and Yescarta (TM)) were recently approved by the FDA. KymriahTM is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and YescartaTM is for the treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T cell therapies lysing CD19-positive targets. Their dramatic efficacy in the short term has been highlighted by many media reports. By contrast, their glaring safety gaps behind the miracles remain much less addressed. Here, we focus on addressing the crucial challenges in relation to the gaps.
引用
收藏
页码：1175 / 1182
页数：8
相关论文
共 16 条
  • [1] Long-term outcomes following CAR T cell therapy: what we know so far
    Cappell, Kathryn M.
    Kochenderfer, James N.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (06) : 359 - 371
  • [2] Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy
    Cheng, Hai
    Ji, Shengwei
    Wang, Jiaojiao
    Hua, Tian
    Chen, Zihan
    Liu, Jiaying
    Shao, Lingyan
    Wang, Xue
    Chen, Wei
    Sang, Wei
    Qi, Kunming
    Li, Zhenyu
    Sun, Cai
    Shi, Ming
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Fei, Xiaoming
    Huang, Hongming
    Gu, Weiying
    Xu, Kailin
    Zheng, Junnian
    Cao, Jiang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 5241 - 5254
  • [3] Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
    Liang, Emily C.
    Albittar, Aya
    Huang, Jennifer J.
    Hirayama, Alexandre, V
    Kimble, Erik L.
    Portuguese, Andrew J.
    Chapuis, Aude
    Shadman, Mazyar
    Till, Brian G.
    Cassaday, Ryan D.
    Milano, Filippo
    Kiem, Hans -Peter
    Riddell, Stanley R.
    Turtle, Cameron J.
    Maloney, David G.
    Gauthier, Jordan
    BLOOD ADVANCES, 2023, 7 (22) : 6990 - 7005
  • [4] Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas
    de Masson, A.
    Guitera, P.
    Brice, P.
    Moulonguet, I.
    Mouly, F.
    Bouaziz, J. -D.
    Battistella, M.
    Madelaine, I.
    Roux, J.
    Ram-Wolff, C.
    Cayuela, J. -M.
    Bachelez, H.
    Bensussan, A.
    Michel, L.
    Bagot, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) : 720 - 724
  • [5] Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer
    Jin, Chuan
    Fotaki, Grammatiki
    Ramachandran, Mohanraj
    Nilsson, Berith
    Essand, Magnus
    Yu, Di
    EMBO MOLECULAR MEDICINE, 2016, 8 (07) : 702 - 711
  • [6] CD19 CAR-T cell therapy for relapsed / refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
    Zhang, Li-Na
    Song, Yongping
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [7] Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy
    Chen, Gregory M.
    Chen, Changya
    Das, Rajat K.
    Gao, Peng
    Chen, Chia-Hui
    Bandyopadhyay, Shovik
    Ding, Yang-Yang
    Uzun, Yasin
    Yu, Wenbao
    Zhu, Qin
    Myers, Regina M.
    Grupp, Stephan A.
    Barrett, David M.
    Tan, Kai
    CANCER DISCOVERY, 2021, 11 (09) : 2186 - 2199
  • [8] CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
    Li, Zhihui
    Yang, Keyan
    Song, Yanzhi
    Zhao, Yongqiang
    Wu, Fan
    Wen, Xiaopei
    Li, Jing
    Wang, Xianxuan
    Xu, Teng
    Zheng, Xiaoyu
    Zheng, Qinglong
    Wu, Tong
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [9] Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
    Xu, Hao
    Li, Ningwen
    Wang, Gaoxiang
    Cao, Yang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [10] Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation
    Kubo, Ryuta
    Onodera, Koichi
    Onishi, Yasushi
    Fukuhara, Noriko
    Harigae, Hideo
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 841 - 845
12